Related Experiment Video
Updated: May 15, 2026
07:35
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
Amplified RPS6KB1 and CDC2 genes are potential biomarkers for aggressive HIV+/EBV+ diffuse large B-cell lymphomas
Xianfeng F Zhao1, Merry Y Zhao, Ling Chai
1Department of Pathology, Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. Frank.Zhao2@va.gov
International Journal of Clinical and Experimental Pathology
|January 19, 2013
Summary
Amplified RPS6KB1 and CDC2 genes are potential biomarkers for aggressive diffuse large B-cell lymphoma (DLBCL), especially in HIV-positive and EBV-positive patients. Targeting these genes may offer new treatment strategies for this aggressive lymphoma.
Area of Science:
- Oncology
- Virology
- Molecular Biology
Background:
- RPS6KB1 (p70S6K/p85S6K) and CDC2 (cdc2) are key genes involved in cell signaling and cell cycle progression.
- Previous research indicated common amplification of RPS6KB1 and CDC2 in Epstein-Barr virus-positive (EBV+) diffuse large B-cell lymphoma (DLBCL) among HIV patients.
- Aggressive B-cell lymphomas, particularly those associated with HIV and EBV co-infection, represent a significant clinical challenge.
Purpose of the Study:
- To evaluate the amplification frequency of RPS6KB1 and CDC2 genes in HIV-related and non-HIV-related DLBCL.
- To assess the diagnostic potential of RPS6KB1 and CDC2 gene amplification in distinguishing specific DLBCL subtypes.
- To explore the therapeutic implications of targeting amplified RPS6KB1 and CDC2 in aggressive DLBCL.
Main Methods:
- Real-time quantitative PCR was employed to quantify RPS6KB1 and CDC2 gene amplification.
- Analysis included 12 HIV-related aggressive B-cell lymphomas and 10 non-HIV-related DLBCL cases, categorized by HIV and EBV status.
- Receiver operating characteristic (ROC) curve analysis and Mann-Whitney U statistic were used to determine the area under the curve (AUC) for gene discrimination.
Main Results:
- Amplified RPS6KB1 and CDC2 genes were more prevalent in DLBCL subtypes commonly associated with HIV infection.
- The AUC values indicated a significant ability of both RPS6KB1 (0.76) and CDC2 (0.74) to differentiate between specific patient groups.
- Gene amplification patterns varied across the four studied groups (HIV-/EBV-, HIV-/EBV+, HIV+/EBV-, HIV+/EBV+).
Conclusions:
- Amplified RPS6KB1 and CDC2 serve as potential biomarkers for aggressive DLBCL, particularly in the context of HIV and EBV co-infection (HIV+/EBV+).
- These findings suggest that targeting RPS6KB1 and CDC2 could represent a promising therapeutic strategy for HIV+/EBV+ aggressive DLBCL.
- Further research is warranted to validate these biomarkers and explore targeted treatment modalities.
Related Concept Videos
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...